GELITA, a global leader in collagen protein solutions, will showcase its latest advancements in excipient technology at BIO International 2026 in San Diego (Booth 3335-DF). Renowned for its expertise in gelatin and collagen peptides, GELITA continues to set new standards for safety, performance, and sustainability in the pharmaceutical and medical device sectors.
GELITA’s Endotoxin Controlled Excipients (ECE) portfolio is engineered to meet the highest demands of today’s biomedical landscape. With rigorous endotoxin control, these excipients ensure maximum safety, biocompatibility, and regulatory compliance, paving the way for breakthroughs in drug delivery, vaccine stabilization, tissue engineering, 3D bioprinting, and regenerative medicine. Researchers and manufacturers benefit from reliable, high-purity ingredients that support the development of innovative and life-saving therapies.
Spotlight on MEDELLAPRO® and VACCIPRO®
At BIO International, GELITA will feature two flagship products from its ECE portfolio:
- MEDELLAPRO® (gelatin): Recognized for outstanding biocompatibility and formulation flexibility, MEDELLAPRO® enables the creation of advanced biomedical products, from surgical sealants and hemostatic agents to scaffolds and drug delivery systems.
- VACCIPRO® (collagen peptides): Trusted for stabilizing vaccines and injectables, VACCIPRO® offers low allergenic potential, high tolerability, and protects sensitive molecules.
Introducing Ultra Low Endotoxin Innovation
GELITA is setting a new benchmark in purity with the launch of MEDELLAPRO® Ultra Low Endotoxin gelatin, featuring less than 10 endotoxin units per gram. This next-generation grade is specifically engineered for the most sensitive biomedical applications, enabling the production of highly reproducible and biocompatible hydrogels. MEDELLAPRO® with ultra-low endotoxin level provides researchers and manufacturers with a reliable solution for demanding projects where safety and consistent quality are paramount.
Scientific Presentation: The Future of Biomedical Collagen
With a steadfast commitment to quality and innovation, GELITA is also advancing biotechnological processes to develop animal-free, recombinant collagen proteins - offering resource-efficient and sustainable solutions for the future. As part of the conference program, GELITA will host a scientific lecture:
- Title: The Role of Non-Animal Recombinant Collagen Proteins in Biomedical Applications: From Vaccine Stabilization to Artificial Organs
- Presenter: Dr. Michelle Montgomery - PhD in Biochemistry and Molecular Biology - Senior Manager R&D GELITA
- Date & Time: Tuesday, June 23, 2026, at 2:45 PM – Theatre 4
Visit GELITA at Booth 3335-DF in the German Pavilion to discover how MEDELLAPRO® and VACCIPRO® are shaping the future of vaccine development, medical devices, and biomedical innovation.
GELITA’s Endotoxin Controlled Excipients (ECE) portfolio is engineered to meet the highest demands of today’s biomedical landscape. With rigorous endotoxin control, these excipients ensure maximum safety, biocompatibility, and regulatory compliance, paving the way for breakthroughs in drug delivery, vaccine stabilization, tissue engineering, 3D bioprinting, and regenerative medicine. Researchers and manufacturers benefit from reliable, high-purity ingredients that support the development of innovative and life-saving therapies.
Spotlight on MEDELLAPRO® and VACCIPRO®
At BIO International, GELITA will feature two flagship products from its ECE portfolio:
- MEDELLAPRO® (gelatin): Recognized for outstanding biocompatibility and formulation flexibility, MEDELLAPRO® enables the creation of advanced biomedical products, from surgical sealants and hemostatic agents to scaffolds and drug delivery systems.
- VACCIPRO® (collagen peptides): Trusted for stabilizing vaccines and injectables, VACCIPRO® offers low allergenic potential, high tolerability, and protects sensitive molecules.
Introducing Ultra Low Endotoxin Innovation
GELITA is setting a new benchmark in purity with the launch of MEDELLAPRO® Ultra Low Endotoxin gelatin, featuring less than 10 endotoxin units per gram. This next-generation grade is specifically engineered for the most sensitive biomedical applications, enabling the production of highly reproducible and biocompatible hydrogels. MEDELLAPRO® with ultra-low endotoxin level provides researchers and manufacturers with a reliable solution for demanding projects where safety and consistent quality are paramount.
Scientific Presentation: The Future of Biomedical Collagen
With a steadfast commitment to quality and innovation, GELITA is also advancing biotechnological processes to develop animal-free, recombinant collagen proteins - offering resource-efficient and sustainable solutions for the future. As part of the conference program, GELITA will host a scientific lecture:
- Title: The Role of Non-Animal Recombinant Collagen Proteins in Biomedical Applications: From Vaccine Stabilization to Artificial Organs
- Presenter: Dr. Michelle Montgomery - PhD in Biochemistry and Molecular Biology - Senior Manager R&D GELITA
- Date & Time: Tuesday, June 23, 2026, at 2:45 PM – Theatre 4
Visit GELITA at Booth 3335-DF in the German Pavilion to discover how MEDELLAPRO® and VACCIPRO® are shaping the future of vaccine development, medical devices, and biomedical innovation.
